Tranexamic Acid for Melasma

Tranexamic acid is an antifibrinolytic. It reversibly blocks the lysine binding sites on plasminogen, which stops plasminogen activator from converting plasminogen into plasmin.

That is a bleeding mechanism, and it is what the drug is licensed for. The oral tablet carries one FDA indication, cyclic heavy menstrual bleeding in females of reproductive potential, while the intravenous form carries a separate one, short-term use in hemophilia to reduce bleeding around tooth extraction. The pigment connection runs through the same pathway inside skin. Plasminogen is present in human epidermal basal cells and cultured keratinocytes are known to produce plasminogen activator, which gives a basic rationale that tranexamic acid alters keratinocyte function and the way those cells signal after ultraviolet exposure. Melasma sits on sun-exposed skin, so damping a UV-triggered signaling route is the theory. The same review that lays out the mechanism says the clinical evidence is not yet established adequately.

The anchor study is a double-blind, placebo-controlled trial. Forty-four enrolled and 39 completed; everyone got sunscreen, half got 250 mg of tranexamic acid twice daily for three months, and at three months the modified Melasma Area and Severity Index fell 49% in the treated arm against 18% in the control arm, with severe melasma improving more than moderate melasma. It was a single-center study enrolling predominantly Hispanic women, so read it as a real signal on a narrow population rather than a settled answer.

The largest real-world dataset points the same way. Across 561 treated cases in a Singapore tertiary center, 503 (89.7%) improved, 56 (10.0%) did not, and 2 (0.4%) worsened, with a median treatment length of four months and response usually visible within two months. Pooling is more cautious: a meta-analysis of 24 randomized trials found tranexamic acid added to routine treatment beat routine treatment alone at 4, 8, 12 and 16 weeks, but that advantage was not detected when the topical or intradermal route was used.

Severity works in your favor here, which is unusual. In the placebo-controlled trial, those with severe melasma improved more than those with moderate melasma. Family history works against you: in the 561-case series, response was 90.6% without a family history of melasma against 60.0% with one (P = .01).

That single split is worth asking your own family about before you set expectations for a 12-week course.

The shape of the condition matters too. A 2025 Latin American expert consensus describes melasma as a chronic, relapsing hyperpigmentation disorder of photoexposed areas, most frequent in adult women with darker skin phototypes, driven by sun exposure, sex hormones such as pregnancy, and genetic predisposition. Oral tranexamic acid is generally reached for when rigorous photoprotection and topical agents have not been enough. The gate on the way in is not your skin type, it is your clotting history.

A network meta-analysis compared the routes head to head. Oral tranexamic acid combined with routine topical agents produced a larger MASI change than intradermal, topical or microneedled tranexamic acid at weeks 4, 8 and 12 and at last follow-up; oral alone separated from placebo by week 4 while the other routes took until week 8. The same analysis adds a caveat you should hold onto: over the longer run, tranexamic acid used on its own showed no route advantage at all.

Topical is not useless, it is just slower and less well evidenced. In a split-face randomized study of 50 with melasma, microneedling plus topical 4% tranexamic acid every other week cut modified MASI by 57.4% while nightly 4% hydroquinone on the other side cut it 54.8%, a difference that did not reach significance. That was a prescription-strength preparation applied under a procedure. A shelf serum is a different thing. A tranexamic acid serum sold as a cosmetic has not been through an FDA drug review and should not be read as equivalent to either arm of that trial.

Topicals still hold the strongest comparative evidence. A Cochrane review of 20 studies and 2,125 participants found triple-combination cream (hydroquinone, tretinoin and fluocinolone acetonide) more effective at lightening melasma than hydroquinone alone, with a risk ratio of 1.58 (95% CI 1.26 to 1.97). The same review concluded that study quality across the field was generally poor and available treatments inadequate, which is exactly why an off-label systemic option got attention in the first place.

US access has changed underneath this. The FDA states there are no FDA-approved or otherwise legally marketed over-the-counter skin lightening products, that unapproved ones had to leave the market effective September 23, 2020, and that the only FDA-approved drug containing hydroquinone is a prescription triple-combination cream for short-term treatment of moderate to severe facial melasma. That cream's own label warns it may produce exogenous ochronosis, a gradual blue-black darkening of the skin, and states it is not indicated for maintenance treatment. Tranexamic acid usually goes on top of that. It does not replace it.

The gap between the two uses is large. The approved regimen for heavy menstrual bleeding is 1,300 mg three times a day, 3,900 mg per day, for a maximum of five days per cycle. The melasma trials used 250 mg twice daily, taken continuously for 12 weeks, which is about an eighth of that daily total. Pushing higher has been tested and did not pay: randomizing 50 with moderate to severe facial melasma to 250 mg twice daily against 500 mg twice daily gave a 75% mMASI response in 20% and 25% respectively (p = 0.71).

On timing, two datasets agree. In a randomized trial of 260, mean MASI fell significantly at both 8 and 12 weeks when oral tranexamic acid was added to routine topical measures, while the topical-only group's improvement was significant at 8 weeks and no longer significant at 12, and most of those who responded in the 561-case series did so within two months. One practical US wrinkle: the only oral strength marketed here is a 650 mg tablet, so how a low daily dose is built from that tablet is a decision for the clinician writing it, and not one to improvise.

Start with what the label forbids. Oral tranexamic acid is contraindicated with concomitant combined hormonal contraception, in active thromboembolic disease such as deep vein thrombosis, pulmonary embolism or cerebral thrombosis, with a history of thrombosis or thromboembolism including retinal vein or artery occlusion, and with an intrinsic risk of thrombosis such as thrombogenic valvular disease, thrombogenic cardiac rhythm disease or hypercoagulopathy. The label singles out women who are obese or who smoke, especially smokers over 35, as a particular concern for the contraceptive interaction.

Now what the melasma-dose evidence shows, which is reassuring without being a clean bill. A 2025 systematic review reported no thromboembolic events observed in randomized controlled trials of oral tranexamic acid, and the 561-case series recorded adverse events in 40 (7.1%), mostly transient, with one deep vein thrombosis in a woman later given a diagnosis of familial protein S deficiency; its authors concluded that careful screening for personal and familial thromboembolism risk should be done before starting. Expect questions about recent surgery and long immobility too. Neither wave this away nor let it scare you off the conversation.

Because melasma is not on the label, whoever writes the prescription is making a case-by-case clinical judgment rather than following an approved indication. A responsible intake asks about personal and family clot history, current contraception, smoking, pregnancy or breastfeeding status, and eye history. Kidney function belongs there as well: the approved label reduces dosing in stages once serum creatinine rises above 1.4 mg/dL. If an online form skips all of that and simply ships tablets, treat the omission as the answer to your question about the service.

Diagnosis is the other half of the intake. Facial hyperpigmentation has several causes and they do not respond alike. The 2025 Latin American consensus starts with establishing an accurate diagnosis, assessing the impact on quality of life and grading severity before any active therapy is chosen, then reassessing periodically and changing course if targets are not met. Standardized photographs at week zero give you and the clinician something to compare against at week 12, which is the point where the decision to continue or stop gets made.

Ordinary broad-spectrum sunscreen is not the whole job. Sixty-eight with melasma were randomized for eight weeks, all on 4% hydroquinone, to either a sunscreen containing iron oxide as a visible-light-absorbing pigment or a UV-only sunscreen, both SPF 50 or higher; the iron-oxide group showed 15% greater improvement in MASI, 28% greater in colorimetric values and 4% greater in melanin assessment.

The authors read that as evidence visible light itself contributes to melasma. Tinted mineral formulas are where that iron oxide usually lives.

Stacking is the intended use rather than a bonus. Oral tranexamic acid combined with routine topical agents was the strongest arm in the route comparison, the approved triple-combination cream instructs daily SPF 30 and sun avoidance as part of the regimen, and the Latin American consensus keeps topical depigmenting agents and strict photoprotection running after remission specifically to prevent recurrence. Skipping the sunscreen and keeping the tablet inverts the order of what the evidence supports.

The drug itself is cheap. The federal National Average Drug Acquisition Cost file published on 2 September 2026 lists generic tranexamic acid 650 mg tablets at $0.85674 per tablet. That is what pharmacies pay to acquire it. Treat it as a floor under your own price. Consultation fees, shipping and any topical or tinted sunscreen sit on top of it. We are not quoting a monthly figure for a specific telehealth service on this page because we have not verified one against a live source, and a plausible-looking number would be worse than none.

Judge a prescriber on the screening and the exit plan. You want someone who takes a clotting and contraception history in writing, grades severity against photographs, sets the 12-week review date at the start, and tells you what maintenance looks like afterwards. Whether any of this suits you is a licensed clinician's decision, and this page is information, not medical advice. That last point about maintenance catches most off guard: relapse ran at 27.2% among those who improved in the 561-case series, gains in the placebo-controlled trial narrowed from 49% to 26% three months after treatment stopped, and the approved topical cream's own label states melasma usually recurs upon discontinuation.